Page 162 - 南京医科大学学报自然科学版

第41卷第7期
·1092 · 南 京 医 科 大 学 学 报 2021年7月

Atezolizumab versus docetaxel in patients with previously al. Nivolumab plus ipilimumab in lung cancer with a high
treated non ⁃ small ⁃ cell lung cancer（OAK）：a phase 3， tumor mutational burden［J］. N Engl J Med，2018，378

open ⁃ label，multicentre randomised controlled trial［J］. （22）：2093-2104
Lancet，2017，389（166）：255-265 ［45］ PAZ⁃ARES L，URBAN L，AUDIGIER⁃VALETTE C，et al.
［34］ GALLUZZI L，BUQUÉ A，KEPP O，et al. Immunological CheckMate 817：safety of flat⁃dose nivolumab plus weight⁃
effects of conventional chemotherapy and targeted anti⁃ based ipilimumab for the first⁃line（1L）treatment of ad⁃
cancer agents［J］. Cancer Cell，2015，28（6）：690-714 vanced NSCLC［J］. J Thorac Oncol，2018，13S（10）：S493
［35］ PENG J，HAMANISHI J，MATSUMURA N，et al. Chemo⁃ ［46］ BARLESI F，AUDIGIER ⁃ VALETTE C，FELIP E，et al.
therapy induces programmed cell death⁃ligand 1 overex⁃ CheckMate 817：first⁃line nivolumab plus ipilimumab in
pression via the nuclear factor⁃κB to foster an immunosup⁃ patients with ECOG PS 2 and other special populations
pressive tumor microenvironment in ovarian cancer［J］. with advanced NSCLC［J］. J Thorac Oncol，2019，14S
Cancer Res，2015，75（23）：5034-5045 （10）：S214-S215
［36］ LANGER C J，GADGEEL S M，BORGHAEI H，et al. Car⁃ ［47］ RIZVI N A，CHO B C，REINMUTH N，et al. Durvalumab
boplatin and pemetrexed with or without pembrolizumab with or without tremelimumab vs standard chemotherapy
for advanced，non⁃squamous non⁃small⁃cell lung cancer： in first ⁃ line treatment of metastatic non ⁃ small cell lung
a randomised，phase 2 cohort of the open⁃label KEYNOTE cancer：the MYSTIC phase 3 randomized clinical trial［J］.
⁃021 study［J］. Lancet Oncol，2016，17（11）：1497-1508 JAMA Oncol，2020，6（5）：661-674
［37］ GANDHI L，RODRÍGUEZ⁃ABREU D，GADGEEL S，et ［48］ GARON E B，CHO B C，REINMUTH N，et al. Patient⁃re⁃
al. Pembrolizumab plus chemotherapy in metastatic non⁃ ported outcomes with durvalumab with or without tremeli⁃
small⁃cell lung cancer［J］. N Engl J Med，2018，378（22）： mumab versus standard chemotherapy as first⁃line treat⁃
2078-2092 ment of metastatic non⁃small⁃cell lung cancer（MYSTIC）
［38］ GADGEEL S，RODRIGUEZ⁃ABREU D，SPERANZA G， ［J］. Clin Lung Cancer，2021，doi：10.1016/j. cllc. 2021. 0
et al. Updated analysis from KEYNOTE ⁃ 189：pembroli⁃ 2.010
zumab or placebo plus pemetrexed and platinum for previ⁃ ［49］ HEGDE P S，WALLIN J J，MANCAO C. Predictive mark⁃
ously untreated metastatic nonsquamous non ⁃ small ⁃ cell ers of anti⁃VEGF and emerging role of angiogenesis inhib⁃
lung cancer［J］. J Clin Oncol，2020，38（14）：1505-1517 itors as immunotherapeutics［J］. Semin Cancer Biol，
［39］ PAZ⁃ARES L，LUFT A，VICENTE D，et al. Pembrolizum⁃ 2018，52（Pt 2）：117-124
ab plus chemotherapy for squamous non⁃small⁃cell lung ［50］ SANDLER A，GRAY R，PERRY M C，et al. Paclitaxel⁃
cancer［J］. N Engl J Med，2018，379（21）：2040-2051 carboplatin alone or with bevacizumab for non⁃small⁃cell
［40］ WEST H，MCCLEOD M，HUSSEIN M，et al. Atezolizum⁃ lung cancer［J］. N Engl J Med，2006，355（24）：2542-2550
ab in combination with carboplatin plus nab ⁃ paclitaxel ［51］ RECK M，VON PAWEL J，ZATLOUKAL P，et al. Phase
chemotherapy compared with chemotherapy alone as first⁃ Ⅲ trial of cisplatin plus gemcitabine with either placebo
line treatment for metastatic non ⁃ squamous non ⁃ small ⁃ or bevacizumab as first⁃line therapy for nonsquamous non⁃
cell lung cancer（IMpower130）：a multicentre，ran⁃ small⁃cell lung cancer：AVAil［J］. J Clin Oncol，2009，27
domised，open ⁃ label，phase 3 trial［J］. Lancet Oncol， （8）：1227-1234
2019，20（7）：924-937 ［52］ WALLIN J J，BENDELL J C，FUNKE R，et al. Atezoli⁃
［41］ FACCHINETTI F，BORDI P，LEONETTI A，et al. Profile zumab in combination with bevacizumab enhances antigen
of atezolizumab in the treatment of metastatic non⁃small⁃ ⁃specific T⁃cell migration in metastatic renal cell carcino⁃
cell lung cancer：patient selection and perspectives［J］. ma［J］. Nat Commun，2016，7（12624）：12624
Drug Des Devel Ther，2018，12：2857-2873 ［53］ SOCINSKI M A，JOTTE R M，CAPPUZZO F，et al.
［42］ ROTTE A，JIN J Y，LEMAIRE V. Mechanistic overview Atezolizumab for first ⁃ line treatment of metastatic non⁃
of immune checkpoints to support the rational design of squamous NSCLC［J］. N Engl J Med，2018，378（24）：
their combinations in cancer immunotherapy［J］. Ann On⁃ 2288-2301
col，2018，29（1）：71-83 ［54］ RECK M，MOK T S，NISHIO M，et al. Atezolizumab plus
［43］ LARKIN J，CHIARION⁃SILENI V，GONZALEZ R，et al. bevacizumab and chemotherapy in non ⁃ small ⁃ cell lung
Combined nivolumab and ipilimumab or monotherapy in cancer（IMpower150）：key subgroup analyses of patients
untreated melanoma［J］. N Engl J Med，2015，373（1）： with EGFR mutations or baseline liver metastases in a
23-34 randomised，open⁃label phase 3 trial［J］. Lancet Respir
［44］ HELLMANN M D，CIULEANU T E，PLUZANSKI A，et Med，2019，7（5）：387-401